Haven't had much time lately? Here's what you may have missed in the last few months
New in 2015: Hairy Cell Leukaemia, Myeloproliferative Neoplasms, Thymic Epithelial Tumours, Central Venous Access, Treatment of Dyspnoea
23 Aug 2016
Preliminary findings suggest potential for programmed cell death protein 1 inhibitor therapy in acral and mucosal melanoma and perhaps uveal disease
22 Aug 2016
Findings cast doubt on the benefit of adding chemotherapy to radiotherapy after resection of high-risk salivary gland carcinoma
22 Aug 2016
J. Strosberg digs into results from first randomised study with radiolabelled somatostatin analogue peptides in patients with midgut neuroendocrine tumours (NETs).
19 Aug 2016
Programmed cell death 1 inhibitor-associated pneumonitis patient risk groups identified
18 Aug 2016
Epidermal growth factor receptor status is associated with the likelihood of leptomeningeal metastases and treatment outcomes in non-small-cell lung...
J. Strosberg digs into results from first randomised study with radiolabelled somatostatin analogue peptides in patients with midgut neuroendocrine tumours (NETs). The primary endpoint of progression-free survival is longer at interim analysis with also favourable overall survival and response rate, the data to be confirmed in final analysis. Renal toxicity is tolerable; myelosuppression is in general mild, however, there is a concern of later myelodysplastic syndrome and leukaemia, currently predicted to be low.